Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Centre National De La Recherche Scientifique

Inserm

Sabine Traver

Samir Hamamah

Elodie Scalici

Marcel Mechali

Malik Lutzmann

Bernard De Massy

Corinne Grey

The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or miR_191 or miR_320_a or miR_21 or miR_30_d or miR_574_3p. The method may also be used in predicting the efficacy of controlled ovarian hyperstimulation.

Methods employing circulating DNA and miRNA as biomarkers for female infertility

The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a follicular fluid sample.

Free nucleic acids and miRNA as non-invasive method for determining embryo quality

The composition includes either an isolated protein complex including MCM8 and MCM9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.

Protein complex comprising MCM8 and MCM9 proteins and their use

Growing community of inventors

Montpellier, France

Sabine Traver